Targeting the Mutational Landscape of Bystander Cells: Drug-Promoted Blood Cancer From High-Prevalence Pre-neoplasias in Patients on BRAF Inhibitors. The gene discussed is BRAF; the disease is hematopoietic and lymphoid system neoplasm.